Neoadjuvant HER2+ Articles | Page 3

Stage, ER Status Guide HER2 Therapy Selection in Breast Cancer
The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status. 
Finding the Right Place for Dual HER2 Blockade in Breast Cancer and Beyond
Although drugs that target HER2 have transformed the prognosis for many patients with breast cancer, the development of resistant disease remains a significant clinical challenge.
The FDA has extended its decision deadline by 3 months on a biologics license application for MYL-1401O, a trastuzumab biosimilar co-developed by Mylan and Biocon. A final decision is expected on or before December 3, 2017.
FDA Grants DS-8201 Breakthrough Designation for HER2+ Breast Cancer
The investigational HER2-targeting antibody-drug conjugate DS-8201 has received an FDA breakthrough therapy designation for the treatment of patients with HER2-positive, locally advanced, or metastatic breast cancer.
Frontline Ribociclib Approved in Europe for HR+/HER2- Breast Cancer
The European Commission has approved the CDK 4/6 inhibitor ribociclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative locally advanced or metastatic breast cancer.
Gradishar Sheds Light on Treatment Trends in Breast Cancer
William J. Gradishar, MD, discusses the latest developments in the HER2-positive setting, as well as biomarker development and the potential for immunotherapy in breast cancer.
Lead Researcher Discusses Latest Pertuzumab Data in HER2+ Breast Cancer
Gunter von Minckwitz, MD, PhD, discusses the APHINITY results and their implication for the use of pertuzumab in patients with HER2-positive breast cancer.
Neoadjuvant T-DM1 Improves pCR in HER2+/HR+ Early Breast Cancer
Twelve weeks of neoadjuvant T-DM1 with or without endocrine therapy induced superior pathologic complete response compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.
Pegram Discusses Latest Developments in HER2+ Breast Cancer
Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.
Sequenced Treatment Making Inroads in HER2-Positive Early Breast Cancer
The introduction of targeted therapies has transformed HER2-positive breast cancer from an aggressive disease with poor outcomes to a highly manageable disease with potential for long-term survival.
Publication Bottom Border
Border Publication